

SEP - 4 2003

K031919
page 1 of 2

510(k) Summary

This 510(k) Summary for the modified EBI[®] XFIX[®] DFS[®] System is provided as required per Section 513(3) of the Food, Drug and Cosmetic Act.

1. Sponsor: EBI, L.P.
100 Interpace Parkway
Parsippany, NJ 07054

Contact Person: Peter Allan
Telephone: (973) 299-9300, x3329

Date prepared: June 20, 2003

2. Proprietary Name: EBI[®] XFIX[®] DFS[®] System

Common Name: External Fixation Device

Classification Names: Single/Multiple Component Metallic Bone Fixation Appliances and Accessories, 21 CFR 888.3030

3. Predicate or Legally Marketed Device:

- EBI[®] XFIX[®] DFS[®] System – EBI, L.P. (K953406)

4. Description of the device:

The System consists of external fixation components and implantable bone screws. The EBI XFIX DFS System is utilized in the following manner: bone screws are inserted through the patient's skin and soft tissue and into the bone. The fixator frame of the EBI XFIX DFS System is attached to the shanks of the bone screws. The intended use and fundamental scientific technology have not changed from the previously cleared submission. This submission is only for the addition of carbon fiber material for the Central Body Component, Ankle Clamp, and T-Clamp.

5. Intended Use:

The EBI[®] XFIX[®] DFS[®] System is intended for use in the treatment of bone conditions including leg lengthening, osteotomies, arthrodesis, fracture fixation, and other bone conditions amenable to treatment by use of the external fixation modality.

6. Materials:

The components of the System may be manufactured from materials such as aluminum, stainless steel, titanium alloy, and carbon fiber.

7. Comparison of the technological characteristics of the device to predicate devices:

The modified EBI[®] XFIX[®] DFS[®] System is substantially equivalent to the following predicate device:

EBI XFIX DFS System (K953406)

- The modified EBI XFIX DFS System is fabricated from the same materials as the components of the currently marketed EBI XFIX DFS Fixation System.
- The modified EBI XFIX DFS System and the currently marketed EBI XFIX DFS System are both indicated for the treatment of bone conditions, including leg lengthening, osteotomies, arthrodesis, fracture fixation, and other bone conditions amenable to treatment by use of the external fixation modality.
- The bone screw clamps of the modified EBI XFIX DFS System, like the bone screw clamps currently marketed in the EBI XFIX DFS System, are designed for attachment to the bone screws.
- The additional component of the EBI XFIX DFS System, like the components of the currently marketed EBI XFIX DFS System, is provided non-sterile.
- There are no significant differences between the modified EBI XFIX DFS System and the currently marketed EBI XFIX DFS System. It is substantially equivalent* to the predicate device with regard to intended use, materials, and function.

*Any statement made in conjunction with this submission regarding a determination of substantial equivalence to any other product is intended only to relate to whether the product can be lawfully marketed without pre-market approval or reclassification and is not intended to be interpreted as an admission or any other type of evidence in patent infringement litigation. [Establishment Registration and Premarket Notification Procedures, Final Regulation, Preamble, August 23, 1977, FR 42520 (Docket No. 76N-0355.)]



SEP - 4 2003

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. Peter Allan
Regulatory Affairs Associate
EBI, L.P.
100 Interpace Parkway
Parsippany, NJ 07054

Re: K031919
Trade/Device Name: EBI[®] XFIX[®] DFS[®] System
Regulation Numbers: 21 CFR 888.3030
Regulation Names: Single/multiple component metallic bone fixation appliances and accessories
Regulatory Class: II
Product Codes: KTT
Dated: June 20, 2003
Received: June 23, 2003

Dear Mr. Allan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Mr. Peter Allan

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten". The signature is written in a cursive style with a long horizontal line extending to the right.

Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

STATEMENT OF INDICATIONS FOR USE


Page 1 of 1

510(k) Number (if known): K031919

Device Name: EBI[®] XFIX[®] DFS[®] System

Indications For Use:

The EBI[®] XFIX[®] DFS[®] System is a unilateral external fixation device intended for use in the treatment of bone conditions including leg lengthening, osteotomies, arthrodesis, fracture fixation, and other bone conditions amenable to treatment by use of the external fixation modality.


(Division Sign-Off)
Division of General, Restorative
and Neurological Devices

510(k) Number K031919

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use _____
(Per 21 CFR 801.109)

OR

Over-The-Counter Use

(Optional Format 1-2-96)